How Antibiotics Kill Bacteria — and Why Resistance Is Outpacing New Drugs

The Drug That Changed Medicine—and the Bacteria Now Defeating It

In 1928, Alexander Fleming noticed that a mold contaminating one of his petri dishes had killed the surrounding Staphylococcus bacteria. The mold was Penicillium notatum; the substance it produced was penicillin. By 1945, mass production had made penicillin widely available, and Fleming, Howard Florey, and Ernst Boris Chain shared the Nobel Prize for the discovery. Penicillin transformed medicine: infections that had killed soldiers in World War One were curable by World War Two. Fleming, in his Nobel acceptance speech, warned that misuse of penicillin would produce resistant bacteria. He was right. Today, antimicrobial resistance (AMR) kills 1.27 million people annually worldwide—more than HIV/AIDS or malaria—and is projected to cause 10 million deaths per year by 2050 if current trends continue.

Three Ways Antibiotics Kill Bacteria

Antibiotics are not a single mechanism—they are a collection of chemically diverse compounds that exploit specific vulnerabilities in bacterial biology. All three major mechanisms target features that bacteria have but human cells do not (or possess in sufficiently different forms to minimize toxicity).

Cell Wall Synthesis Inhibition: Bacteria (unlike human cells) are surrounded by a peptidoglycan cell wall that maintains structural integrity under osmotic pressure. Without it, bacteria burst. Beta-lactam antibiotics—penicillins, cephalosporins, carbapenems—bind to and inhibit penicillin-binding proteins (PBPs), enzymes that cross-link peptidoglycan chains. New bacteria produced during cell division fail to build a functional wall and lyse. This mechanism is the basis for some of the most widely used antibiotics in history.

Protein Synthesis Inhibition: Bacterial ribosomes (70S, composed of 30S and 50S subunits) differ structurally from human ribosomes (80S). Antibiotics can exploit this difference to block bacterial protein production without affecting the host. Aminoglycosides (like streptomycin) bind the 30S subunit, causing misreading of mRNA. Macrolides (like erythromycin) and tetracyclines target different sites on the 50S and 30S subunits respectively, stalling translation. Chloramphenicol inhibits peptide bond formation at the 50S subunit.

DNA Replication and Transcription Inhibition: Fluoroquinolones (ciprofloxacin, levofloxacin) inhibit bacterial topoisomerases—enzymes (DNA gyrase and topoisomerase IV) that manage DNA coiling during replication. Without functional topoisomerases, replicating bacteria accumulate DNA strand breaks and die. Rifampicin inhibits bacterial RNA polymerase, blocking transcription. Both target bacterial enzymes structurally distinct enough from human versions to achieve selective toxicity.

How Resistance Develops and Spreads

Antibiotic resistance is not created by antibiotics—it exists spontaneously in bacterial populations as random mutations occur during replication. Antibiotics are a selective pressure: in a population of a trillion bacteria, even a tiny fraction with a resistance mutation will survive and reproduce when the drug is applied. Within days, the population shifts toward the resistant strain. This is Darwinian evolution happening on a human-observable timescale.

What makes the resistance crisis especially severe is horizontal gene transfer—bacteria can share resistance genes directly with other bacteria through plasmids (small rings of DNA) without reproducing. A bacterium can pick up a plasmid carrying multiple resistance genes from an unrelated bacterium in the same environment. This means resistance can spread between different bacterial species, across geographic borders, and between clinical and agricultural settings far faster than evolutionary mutation alone would allow.

• A single bacterium can conjugate (share plasmids) with hundreds of other bacteria per hour
• Plasmids can carry resistance genes for multiple drug classes simultaneously—enabling "one acquisition, total resistance"
• Resistance genes persist in environments long after antibiotic use stops, maintained in soil bacteria by other selective pressures
• Global travel can transport resistant bacteria across continents in hours

MRSA and the Resistance Hierarchy

Methicillin-resistant Staphylococcus aureus (MRSA) became a major clinical problem in the 1960s, shortly after methicillin's introduction in 1959. MRSA produces an altered penicillin-binding protein (PBP2a, encoded by the mecA gene) that beta-lactam antibiotics cannot bind effectively—rendering the entire class useless. MRSA causes 100,000+ deaths annually in the U.S. and Europe combined and remains one of the most feared hospital-acquired infections.

The WHO publishes a "Priority Pathogens" list of bacteria for which new antibiotic development is most urgently needed.

Agriculture's Role in Resistance

Approximately 73% of all antibiotics consumed globally are used in livestock agriculture—primarily as growth promoters and disease prevention in crowded conditions, not to treat sick animals. This massive, diffuse use of antibiotics maintains constant selective pressure on bacteria in agricultural environments, producing resistant strains that can transfer to humans through food, water, or direct contact. The European Union banned antibiotic growth promoters in livestock in 2006; the U.S. FDA's Veterinary Feed Directive (effective 2017) requires veterinary oversight for antibiotic use in food animals—a significant policy shift, though enforcement varies.

Antibiotic Stewardship: What Slows the Crisis

Antibiotic stewardship programs—systematic efforts to ensure antibiotics are used only when necessary, at the right dose, for the appropriate duration—have demonstrated measurable impact in hospital settings. A 2017 meta-analysis of 32 studies found that stewardship programs reduced inappropriate antibiotic use by 24% and Clostridioides difficile infections by 30–50%. The key principles are:

• Prescribe only after confirmed bacterial infection (not viral); rapid diagnostic tests help
• Use the narrowest-spectrum antibiotic effective against the identified organism
• Prescribe the correct dose—underdosing creates resistance, overdosing increases side effects
• Limit duration to what is clinically necessary; shorter courses often achieve equivalent outcomes
• Reserve "last resort" antibiotics (carbapenems, colistin) for confirmed resistant infections only

New antibiotic classes are urgently needed. Since 2000, fewer than 20 truly novel antibiotic classes have reached market—far less than the 20th century's peak discovery rate. The economic problem is structural: a drug used for 5–10 days cannot generate the revenue of a drug taken daily for decades, reducing pharmaceutical investment incentives. This market failure is now recognized as a public health emergency requiring government intervention through "push and pull" funding mechanisms. The biology is solvable. The economics may be the harder problem.